Hanchun NIU, Xiaoyun LI, Mingming BAI, et al. Effect of Shuanglong Antifibrin Capsule on KL-6 and T lymphocyte subsets in patients with connective tissue disease associated with pulmonary fibrosis. [J]. Shanghai Journal of Traditional Chinese Medicine 55(5):41-45(2021)
DOI:
Hanchun NIU, Xiaoyun LI, Mingming BAI, et al. Effect of Shuanglong Antifibrin Capsule on KL-6 and T lymphocyte subsets in patients with connective tissue disease associated with pulmonary fibrosis. [J]. Shanghai Journal of Traditional Chinese Medicine 55(5):41-45(2021) DOI: 10.16305/j.1007-1334.2021.2005149.
Effect of Shuanglong Antifibrin Capsule on KL-6 and T lymphocyte subsets in patients with connective tissue disease associated with pulmonary fibrosis
Objective,2,To observe the efficacy of Shuanglong Antifiber Capsule (SAC) in patients with connective tissue disease associated with pulmonary fibrosis and its effect on serum KL-6 and T lymphocyte subsets in peripheral blood.,Methods,2,A total of 80 patients with pulmonary fibrosis in connective tissue disease were randomly divided into treatment group and control group, 40 cases in each group. On the basic treatment, the treatment group was treated with SAC, and the control group was treated with placebo. The treatment course was 12 weeks. The TCM syndrome score, high resolution CT(HRCT) score, peripheral blood T lymphocyte subsets (CD4,+, CD8,+,) levels and serum levels of KL-6 were compared between the two groups.,Results,2,①During the treatment, 2 cases were lost and 38 cases were completed the experiment in each group.②After treatment, the TCM syndrome scores and serum KL-6 level of both groups were decreased (,P,<,0.05), but the HRCT scores of both groups were no significant changes (,P,>,0.05). The TCM syndrome scores and serum KL-6 level in the treatment group were lower than those in the control group (,P,<,0.05).But the HRCT scores were no statistical difference between the two groups (,P,>,0.05). ③After treatment, CD4,+,T lymphocytes and CD4,+,/CD8,+, in the treatment group were increased (,P,<,0.05), and CD8,+, T lymphocytes were decreased (,P,<,0.05), while there were no significant changes in CD4,+,T lymphocytes, CD8,+, T lymphocytes and CD4,+,/CD8,+, in the control group (,P,>,0.05).After treatment, CD4,+,T lymphocytes, CD8,+,T lymphocytes and CD4,+,/CD8,+, in the treatment group were better than those in the control group (,P,<,0.05).,Conclusions,2,SAC had good efficacy in the treatment of connective tissue disease associated with pulmonary fibrosis. The mechanism might be associated with the decreased expression of KL-6 which secreted by alveolar epithelial cells Ⅱ. In addition, SAC could improve CD4,+,T lymphocytes and decrease CD8,+,T lymphocytes of the peripheral blood to adjust cellular immunity.
SHIBOSKI C H, SHIBOSKI S C, SEROR R, et al. 2016 American college of rheumatology/European league against rheumatism classification criteria for primary sjögren’s syndrome: a consensus and data-driven methodology involving three international patient cohorts[J]. Arthritis Rheum, 2017, 69(1): 35-45.
ALETAHA D, NEOGI T, SILMAN A J, et al. 2010 rheumatoid arthritis classification criteria: an American college of rheumatology/European league against rheumatism collaborative initiative[J]. Arthritis Rheum, 2010, 62(9): 2569-2581.
VAN DEN HOOGEN F, KHANNA D, FRANSEN J, et al. 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative[J]. Arthritis Rheum, 2013, 65(11): 2737-2747.
RAGHU G, REMY-JARDIN M, MYERS J L, et al. Diagnosis of idiopathic pulmonary fibrosis:an official ATS/ERS/JRS/ALAT clinical practice guideline[J]. Am J Respir Crit Care Med, 2018, 198(5): e44-e68.
OHSHIMO S, YOKOYAMA A, HATTORI N, et al. KL-6,a human MUC1 mucin, promotes proliferation and survival of lung fibrosis[J]. Biochem Bioophys Res Commun, 2005, 338(4): 1845-1852.
XU L, YAN D R, ZHU S L, et al. KL-6 regulated the expression of HGF, collagen and myofibrob last differentiation[J]. Eur Rev Med Pharmacol Sci, 2013, 17(22): 3073-3077.
PAPIRIS S A, VLACHOYIANNOPOULOS P G, MANIATI M A, et al. Idiopathic pulmonary fibrosis and pulmonary fibrosis in diffuse systemic sclerosis: two fibroses with different prognoses[J]. Respiration, 1997, 64(1): 81-85.
PAPIRIS S A, KOLLINTZA A, KARATZA M, et al. CD8+T lymphocytes in bronchoalveolar lavage in idiopathic pulmonary fibrosis[J]. J Inflamm, 2007(4): 14.
Efficacy of Qingfei Huayu Decoction combined with pirfenidone on progressive fibrosing interstitial lung disease associated with rheumatoid arthritis of lung heat and blood stasis syndrome type
Research progress on related mechanism regulation by traditional Chinese herbal medicine in pulmonary fibrosis
Clinical observation on the treatment of diabetic kidney disease (DKD) with Yishen Xiezhuo decoction and valsartan
Yanghe Yifei decoction combined with Western medicine in treatment of 40 patients with pulmonary fibrosis of lung-kidney yang deficiency type
Clinical observation on Zishen Qingqi Granule combined with conventional therapy in treatment of mildly to moderately active SLE
Related Author
No data
Related Institution
Rheumatism Department, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
Graduate School of Heilongjiang University of Traditional Chinese Medicine
The First Affiliated Hospital of Heilongjiang University of Traditional Chinese Medicine
Department of Nephrology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine Affiliated to Shanghai University of Traditional Chinese Medicine
Department of Pulmonary Disease, Huaibei Hospital of Traditional Chinese Medicine